Aldeyra Therapeutics, Inc. (ALDX) Downgraded to Sell at Zacks Investment Research
Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report issued on Tuesday.
According to Zacks, “Aldeyra Therapeutics, Inc. is a biotechnology company. The company’s products target immune-mediated, inflammatory, orphan, and other diseases. It is developing NS2, a compound that binds and traps free aldehydes. Aldeyra Therapeutics, Inc. is based in Burlington, Massachusetts. “
Other analysts have also issued research reports about the company. HC Wainwright set a $18.00 target price on Aldeyra Therapeutics and gave the company a “buy” rating in a report on Wednesday, August 9th. Canaccord Genuity set a $12.00 target price on Aldeyra Therapeutics and gave the company a “buy” rating in a report on Wednesday, June 14th. Cowen and Company reissued an “outperform” rating and issued a $14.00 target price (up previously from $9.00) on shares of Aldeyra Therapeutics in a report on Thursday, September 14th. Finally, ValuEngine lowered Aldeyra Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, September 26th. Two equities research analysts have rated the stock with a sell rating and four have issued a buy rating to the company. Aldeyra Therapeutics has an average rating of “Hold” and an average target price of $15.95.
Aldeyra Therapeutics (NASDAQ:ALDX) last announced its quarterly earnings data on Tuesday, August 8th. The biotechnology company reported ($0.35) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.37) by $0.02. Equities analysts expect that Aldeyra Therapeutics will post ($1.63) EPS for the current year.
TRADEMARK VIOLATION NOTICE: This news story was originally posted by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another domain, it was illegally stolen and republished in violation of U.S. and international copyright and trademark legislation. The original version of this news story can be accessed at https://www.americanbankingnews.com/2017/10/10/aldeyra-therapeutics-inc-aldx-downgraded-to-sell-at-zacks-investment-research.html.
In other Aldeyra Therapeutics news, major shareholder Life Sciences Maste Perceptive bought 200,000 shares of Aldeyra Therapeutics stock in a transaction that occurred on Tuesday, September 19th. The shares were purchased at an average cost of $7.25 per share, for a total transaction of $1,450,000.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 28.40% of the company’s stock.
Institutional investors have recently added to or reduced their stakes in the company. Virtu KCG Holdings LLC purchased a new position in shares of Aldeyra Therapeutics in the 2nd quarter worth about $104,000. Renaissance Technologies LLC purchased a new position in shares of Aldeyra Therapeutics in the 1st quarter worth about $132,000. Hikari Power Ltd raised its holdings in shares of Aldeyra Therapeutics by 186.4% in the 2nd quarter. Hikari Power Ltd now owns 107,858 shares of the biotechnology company’s stock worth $507,000 after purchasing an additional 70,196 shares during the period. Sabby Management LLC purchased a new position in shares of Aldeyra Therapeutics in the 1st quarter worth about $898,000. Finally, Vanguard Group Inc. raised its holdings in shares of Aldeyra Therapeutics by 3.2% in the 2nd quarter. Vanguard Group Inc. now owns 304,633 shares of the biotechnology company’s stock worth $1,431,000 after purchasing an additional 9,407 shares during the period. Institutional investors own 40.06% of the company’s stock.
Aldeyra Therapeutics Company Profile
Aldeyra Therapeutics, Inc, formerly Aldexa Therapeutics, Inc, is a biotechnology company. The Company’s principal activities include raising capital and research and development activities. The Company’s segment is the identification and development of a treatment for diseases related to high levels of aldehydes.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aldeyra Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aldeyra Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.